Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Payables: 2017-2024

Historic Payables for Protagonist Therapeutics (PTGX) over the last 8 years, with Dec 2024 value amounting to $23.7 million.

  • Protagonist Therapeutics' Payables rose 10.27% to $22.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.8 million, marking a year-over-year increase of 2.85%. This contributed to the annual value of $23.7 million for FY2024, which is 22.39% up from last year.
  • Per Protagonist Therapeutics' latest filing, its Payables stood at $23.7 million for FY2024, which was up 22.39% from $19.4 million recorded in FY2023.
  • Protagonist Therapeutics' 5-year Payables high stood at $37.7 million for FY2021, and its period low was $18.5 million during FY2020.
  • For the 3-year period, Protagonist Therapeutics' Payables averaged around $22.7 million, with its median value being $23.7 million (2024).
  • As far as peak fluctuations go, Protagonist Therapeutics' Payables soared by 103.89% in 2021, and later crashed by 33.83% in 2022.
  • Protagonist Therapeutics' Payables (Yearly) stood at $18.5 million in 2020, then spiked by 103.89% to $37.7 million in 2021, then slumped by 33.83% to $25.0 million in 2022, then declined by 22.43% to $19.4 million in 2023, then increased by 22.39% to $23.7 million in 2024.